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ABSTRACT
Background: We assessed the impact on survival of angiogenesis and 
inflammation-related factors, particularly LDH serum levels, platelet, neutrophil and 
lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR), in metastatic colorectal 
cancer patients receiving regorafenib monotherapy.
Methods: LDH serum levels, neutrophil, lymphocyte and platelet counts were 
collected at the start of regorafenib monotherapy. Cut-off values were calculated by 
ROC curve analysis. Survival analyses were performed by Kaplan-Meier method, and 
multivariate analysis by Cox method.
Results: A total of 208 patients were eligible for analysis. Among factors who 
were related with worse overall survival and who maintained their role at the 
multivariate analysis, high platelet count (Exp(b):1.4963, 95% CI:1.0130–2.2103, 
p = 0.0439) and high neutrophil/lymphocyte ratio (Exp(b):1.6963, 95% CI:1.0757–
2.6751, p = 0.0237) were those who more deeply were related to worse overall 
survival. High lymphocyte count (Exp(b):0.4527, 95% CI:0.2801–0.7316, p = 0.0013) 
was correlated with improved overall survival.
Conclusions: High neutrophil, high platelet, low lymphocyte count and/or high 
NLR may represent negative prognostic factors in patients receiving regorafenib 
monotherapy. It is advisable that these factors are taken into account in the design 
of subsequent trials in colorectal cancer patients receiving this drug.
INTRODUCTION
The introduction of regorafenib represented a 
significant step forward in the treatment of metastatic 
colorectal cancer (mCRC) patients. This novel oral 
multikinase inhibitor improved both progression free 
survival (PFS) and overall survival (OS) in heavily pre-
treated patients otherwise not suitable for any further 
active therapy [1]. However, the absence of predictive 
factors for treatment efficacy/resistance along with the 
distinct toxicity profile of this novel compound, requires 
a very well balanced clinical assessment of the risk to 
benefit ratio in each patient potentially candidate to 
such a treatment approach. Indeed, even in carefully 
selected cases, available data seem to indicate that a 
not negligible proportion of patients does not derive 
any benefit from this treatment and is thus exposed to 
unnecessary toxicity.
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It is hypothised that tumour-driven neoangiogenesis 
represents the main biological target of regorafenib: 
molecular mechanisms underlying angiogenesis may be 
then considered as important predictive factors for clinical 
outcome during regorafenib treatment.
The biological link between hypoxia, lactic 
dehydrogenase (LDH) levels and the tumour-driven 
angiogenesis pathway through the abnormal activation 
of the Hypoxia Inducible Factor 1 α (HIF1-α) is well 
established [2, 3]. Since LDH and pro-angiogenesis 
factors are regulated by the same HIF1α-driven molecular 
pathway, high LDH levels are concomitantly present 
along with abnormal activation of the VEGF pathway [4]. 
Accordingly to this biological assumption, Azuma et al [5] 
demonstrated that high LDH serum levels were associated 
with tumour over-expression of VEGFA and VEGFR-1. 
As a clinical consequence it has been speculated that LDH 
levels may represent an indirect indicator of activated 
tumour angiogenesis and worse prognosis [6–7]. In 
CRC, a significantly correlation has been demonstrated 
between LDH overexpression and increased risk of 
metastases, and between high LDH serum levels and 
worse prognosis [8–9]. The role of LDH in CRC patients 
receiving anti-angiogenic therapy is more controversial. 
In an exploratory analysis of the CONFIRM-1 and 
2 trials, median PFS resulted improved with the use of 
PTK/ZK (vatalanib, an oral inhibitor of VEGF-receptors) 
in the subgroup of patients with high serum LDH [10–11]. 
Recently Koukourakis et al also demonstrated that serum 
LDH and tissue LDH-5 are complementary features that 
may help characterizing the activity of LDH in CRC 
[12]. Accordingly with these observations we previously 
suggested that pre-treatment LDH levels may represent a 
relevant factor for the prediction of bevacizumab efficacy 
in an unselected population of CRC patients [13].
Neutrophil, lymphocyte and platelet count have 
been identified as markers of clinical outcome in different 
tumour types, in particular in heavily treated mCRC 
patients.
Leucocytes, including neutrophils and lymphocytes, 
were reported to play an important role in tumour 
inflammation and immunology [16] and to have a 
prognostic value in patients with cancer [14–17]. In 
particular, the neutrophil-to-lymphocyte ratio (NLR) is 
a combined indicator of inflammation and immunology 
activity. In recent years, several studies evaluated the 
prognostic role of NLR in many tumour types, including 
CRC, suggesting that an elevated NLR could be related to 
an adverse outcome [17–23]. The results from a recently 
published meta-analysis indicated that a high pre-treatment 
NLR was significantly related to poorer OS and PFS [23]. 
Recent studies also evaluated the correlation between 
inflammation and tumour response to chemotherapy in 
various tumour types [24–26]. Lissoni et al suggested 
that a decreasing lymphocyte count during chemotherapy 
might be correlated with tumour progression. On the 
contrary lymphocyte count at the end of chemotherapy 
was significantly higher than before treatment in patients 
achieving an objective tumour response [27]. An elevated 
NLR has been shown to represent a predictive factor for 
clinical outcome in patients with liver-only colorectal 
metastases receiving neo-adjuvant chemotherapy [28]. 
Accordingly Chua et al demonstrated an independent 
predictive value in terms of clinical benefit, PFS and 
OS for pre-treatment NLR in patients with unresectable 
mCRC undergoing first-line chemotherapy [29]. Many 
clinical and pre-clinical findings also underscored the 
role of platelets in different tumour related events. 
Activated platelets, in response to tissue impairment, can 
induce a pro-inflammatory response leading to increased 
concentrations of pro-inflammatory and pro-tumorigenic 
factors [30]. Globally the potential link between systemic 
inflammation and tumour angiogenesis and thus the 
hypothetical predictive role of inflammatory markers 
during antiangiogenetic therapies has been evaluated in 
CRC patients treated with bevacizumab with interesting 
insights into the biological mechanisms underlying the 
interaction between inflammation, angiogenesis and anti-
VEGF therapy [31].
Aim of the present study was to assess the role 
of angiogenesis and inflammation-related factors such 
as LDH serum levels, platelet count, neutrophil and 
lymphocyte count, and NLR in predicting clinical outcome 
for pre-treated mCRC patients receiving regorafenib. This 
was done in order to individuate potentially reliable and 
easy to use markers for patients stratification and selection.
RESULTS
Univariate analysis
Globally 208 patients were available for our 
analysis. Median age at the start of treatment was 61 
(Range 32–90). All major clinical characteristics have 
been summarised in table 1. In the global population 
median OS was 3.5 months whereas median PFS was 
2.4 months. Among 202 patients who were assessable for 
response, 10 (5%) achieved at least a partial response, 58 
(29%) obtained disease stabilization and the remaining 
134 (66%) showed progressive disease.
The cut-off point with the highest sensitivity and 
specificity for estimating pre-treatment LDH serum levels, 
neutrophil level, lymphocyte level, platelet count and 
NLR as a function of treatment clinical activity was set 
at 1.21 ULN, 0.96 ULN, 1.77 LLN, 0.54 ULN and 0.38 
respectively after ROC analyses.
Among the 95 (46%) patients showing LDH serum 
levels ≥ 1.21 ULN, median OS was significantly shorter 
than among the remaining 113 (54%) patients (3.3 months 
vs. 7.6 months, HR: 0.43, 95% CI: 0.25–0.53, p < 0.0001) 
(Figure 1). Accordingly, a statistically significant difference 
was evident for median PFS (1.7 months vs. 2.5 months 
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respectively in the LDH levels ≥ vs < 1.21 ULN group; 
HR: 0.48, 95% CI: 0.30–0.59, p < 0.0001) (Figure 2).
Fifty patients (24%) showed a neutrophil level 
≥ 0.96 ULN. In these patients median OS was significantly 
shorter than among the remaining 158 (76%) patients 
(2.9 months vs. 5.2 months respectively; HR:0.35, 95% 
CI: 0.12–0.35, p < 0.0001) (Figure 3). Accordingly a 
statistically significant difference was evident for median 
PFS in patients showing neutrophil level ≥ or < than 0.96 
ULN (1.5 months vs. 2.5 months respectively; HR: 0.42, 
95% CI: 0.18–0.44, p < 0.0001).
Among the 64 (31%) patients showing lymphocyte 
level ≥ 1.77 LLN, median OS was significantly 
better than among the remaining 144 (69%) patients 
(11.08 months vs. 3.3 months respectively; HR: 2.73, 
95%CI: 1.67–3.41, p < 0.0001) (Figure 4). A statistically 
significant difference was also evident for median PFS 
in patients showing lymphocyte level ≥ or < than 1.77 
LLN (2.7 months vs. 2.3 months respectively; HR:1.66, 
95% CI: 1.26–2.33, p = 0.0005).
Among 92 (44%) patients showing a platelet level 
≥ 0.54 ULN, median OS was 3.2 months, whereas in the 
Figure 1: Kaplan-Meier curves for median overall survival (OS) in pre-treated metastatic colorectal cancer patients 
receiving regorafenib according to LDH pre-treatment level < (———-) or ≥ (———-) than 1.21 ULN (the cut-off 
value determined by ROC curve analysis) (7.6 months vs. 3.3 months; HR = 0.43, 95%CI: 0.25–0.53, p < 0.0001).
Figure 2: Kaplan-Meier curves for median progression free survival (PFS) in pre-treated metastatic colorectal cancer 
patients receiving regorafenib according to LDH pre-treatment serum level < (———-) or ≥ (———-) than 1.21 ULN 
(the cut-off value determined by ROC curve analysis) (2.5 months vs. 1.7 months; HR = 0.48, 95%CI: 0.30–0.59, 
p < 0.0001).
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remaining 116 (56%) patients median OS was 6.2 months 
(HR: 0.50, 95%CI: 0.31–0.65, p < 0.0001) (Figure 5). 
Median PFS were also significantly different between 
the 2 groups (2.0 vs 2.6 months respectively; HR: 0.59, 
95%CI: 0.39–0.74, p = 0.0001).
Eighty-two (39%) patients showed a NLR < 0.38 
(the cut-off determined by ROC curve analysis). 
Median OS was 9.8 months vs. 3.1 months in patients 
with NLR < vs ≥ 0.38 respectively (HR: 0.34, 95%CI: 
0.22–0.45, p < 0.0001) (Figure 6). Median PFS was 
also significantly different between the 2 groups (3.4 vs 
2.1 months respectively, HR: 0.46, 95%CI:0.29–0.55, 
p < 0.0001).
All the other clinical variables analysed (age at 
diagnosis, gender, RAS mutation status, number of metastatic 
sites, previous adjuvant chemotherapy, number of previous 
systemic anticancer therapies) were not significantly related 
to clinical outcome (both for OS and PFS) (Table 1).
We also assessed whether dose reductions for any 
reason were related to a different outcome. About 25% 
patients experienced at least 1 dose reduction. In this 
group of patients no statistically significant differences 
Figure 3: Kaplan-Meier curves for median overall survival (OS) in pre-treated metastatic colorectal cancer patients 
receiving regorafenib according to pre-treatment neutrophil count < (———-) or ≥ (———-) than 0.96 ULN (the cut-
off value determined by ROC curve analysis) (5.2 months vs. 2.9 months; HR = 0.35, 95%CI: 0.12–0.35, p < 0.0001).
Figure 4: Kaplan-Meier curves for median overall survival (OS) in pre-treated metastatic colorectal cancer patients 
receiving regorafenib according to pre-treatment lymphocyte count < (———-) or ≥ (———-) than 1.77 LLN (the cut-
off value determined by ROC curve analysis) (3.3 months vs. 11.08 months; HR = 2.73, 95% CI: 1.67–3.41, p < 0.0001)
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were seen for overall survival (p = 0.066) or progression 
free survival (p = 0.44).
Multivariate analysis and development of a 
risk score
At multivariate analysis all the factors that resulted 
significant at the univariate analysis (neutrophil count, 
lymphocyte count, platelet count and NLR) maintained 
their independent role as predictors of different OS, 
except for LDH levels. In particular, high platelet count 
(Exp(b):1.4963, 95%CI:1.0130–2.2103, p = 0.0439) 
and high NLR (Exp(b):1.6963, 95%CI:1.0757–
2.6751, p = 0.0237) were related to worse OS, 
whereas a high lymphocyte level (Exp(b):0.4527, 95% 
CI:0.2801– 0.7316, p = 0.0013) was related to better OS.
On the contrary the only 2 factors that maintained 
their roles as predictors of PFS were a high neutrophil 
Figure 5: Kaplan-Meier curves for median overall survival (OS) in pre-treated metastatic colorectal cancer patients 
receiving regorafenib according to pre-treatment platelets count < (———-) or ≥ (———-) than 0.54 ULN (the cut-
off value determined by ROC curve analysis) (6.2 months vs. 3.2 months; HR = 0.50, 95% CI: 0.31–0.65, p < 0.0001)
Figure 6: Kaplan-Meier curves for median overall survival (OS) in pre-treated metastatic colorectal cancer patients 
receiving regorafenib according to pre-treatment neutrophil/lymphocyte ratio < (———-) or ≥ (———-) than 0.38 
(the cut-off value determined by ROC curve analysis) (9.8 months vs. 3.1 months; HR = 0.34, 95%CI: 0.22–0.45, 
p < 0.0001)
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level and a high NLR, with the latter showing the 
greatest impact on median PFS (Exp(b):1.7332, 
95% CI:1.1752–2.5560, p = 0.0058).
By applying correction for multiple testing errors, all 
factors resulting independently related to overall survival 
maintained their statistical significance (lymphocyte count 
p = 0.0125, neutrophil count p = 0.0166, neutrophil/
lymphocyte count p = 0.025, platelet count p = 0.05).
Among 52 (25%) patients who were negative for 
all risk factors, a significant correlation was found with 
improved OS and PFS if compared with the group of 
patients with at least 1 risk factor. In particular, median 
OS was respectively 15.9 vs 3.1 months (HR: 3.81, 95% 
CI: 2.32–4.82, p < 0.0001) whereas median PFS was 5.9 
vs 2.1 months (HR: 2.62, 95% CI: 2.06–3.86, p < 0.0001). 
(Table 2).
On the basis of the results of the multivariate 
analysis, a prognostic score was developed.
In particular, for the presence of each a risk factor 
(high neutrophil/lymphocyte count, high platelet count, 
high neutrophil count) the patients’ risk score was raised 
by 1. Furthermore, the absence of high lymphocyte count 
was considered as another 2 point increase in the scoring, 
due to the greater role as protective factor of lymphocyte 
count. On this basis, patients’ scoring could range between 
0 (extremely favourable) to 5 (extremely unfavourable). 
When overall survival was assessed on the basis of the 
scoring system, patients with extremely favourable 
prognosis had risk of death compared with patients with 
just 1 risk factor about 6 times lower (HR:0.1627, 95% 
CI:0.08454–0.3130, p < 0.0001). This difference was even 
greater when considering other risk groups (Figure 7). 
This relatively small group of patients (22/208, 11%) had 
a median overall survival that was not still reached at the 
time of data analysis.
DISCUSSION
Despite regorafenib exhibited a small, but 
indisputable survival benefit in CRC patients not suitable 
for any further active treatment, the relevant toxicity 
profile along with the virtual absence of predictive factors 
suggested a careful evaluation of the benefit to risk ratio 
before widespread use in clinical practice.
The results of our analysis supports the idea that 
high pre-treatment NLR, high platelet and neutrophil 
count, and a low lymphocyte count are significantly and 
independently associated with worse clinical outcome in 
mCRC patients treated with regorafenib.
This is not surprising as it is generally accepted 
and demonstrated that the inflammatory process 
involving tumour microenvironment plays a crucial role 
in promoting proliferation, invasion and metastases of 
malignant cells [16, 32]. The infiltrating leucocytes, 
including neutrophils and lymphocytes, are critical factors 
for this biological process. Different proangiogenic factors 
such as the vascular endothelial growth factors originate 
from neutrophils and platelets-induced stimulation in the 
peripheral blood or in the tumour microenvironment and 
are eventually responsible for tumour progression [33]. 
Various clinical data highlighted the role of platelet levels 
in mCRC: a pre-planned sub-group analysis from the 
COIN trial, for example, suggested that patients with a 
high platelet count may not be optimal candidates for an 
intermittent strategy, thus remarking the poor prognostic 
profile of these patients [34].
Lymphocytes have been described as crucial 
components of the adaptive immune system and as 
the cellular basis of cancer immunosurveillance and 
immunoediting [35]. As a biological consequence, tumour 
infiltrating lymphocytes (TILs) have been frequently 
Table 2: Median overall survival (mOS) for different groups of patients stratified according to the 
presence of the different independent prognostic factors as resulted from multivariate analysis 
(high platelets count, high neutrophil count, low lymphocyte count, high neutrophil/lymphocyte 
ratio); p < 0.0001
Score
0 1 2 3
Numberof patients 52 48 60 48
mOS (months) 15.9 3.1 3.4 2.8
Legend
0: patients negative for all risk factors (patients with low platelets count, low neutrophil count, high lymphocyte count, low 
neutrophil/lymphocyte ratio)
1: patients with 1 risk factor among the independent prognostic factors above mentioned
2: patients with 2 risk factors among the independent prognostic factors above mentioned
3: patients with 3 risk factors among the independent prognostic factors above mentioned
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reported as indicator of an effective anti-tumour cellular 
immune response [36]. A low lymphocyte count may be 
responsible for an inadequate host-to-tumour immunologic 
reaction with a consequently decreased response against 
cancer, leading to poor clinical outcome.
The NLR has been already evaluated as prognostic 
factor in many tumour types as well as in CRC, usually 
related to an adverse outcome [17–23]. According to our 
data, NLR has been also indicated as a potentially relevant 
prognostic/predictive factor in CRC patients receiving an 
anti-angiogenic treatment such as bevacizumab [31].
In presence of stronger predictors of worse outcome, 
high LDH lost its independent role in influencing 
survival. In contrast to previous analyses in colorectal 
cancer patients receiving anti-angiogenic treatment in 
our experience high LDH serum levels indicated a trend 
toward a worse clinical outcome, rather than representing 
a predictive factor for response [11, 12]. We believe that 
the different setting analysed in our analysis might explain 
this apparent discrepancy. We can speculate that in early 
lines of treatment hypoxic factors might directly influence 
circulating isoforms of LDH such as LDH5 as predictors 
of efficacy to anti-VEGF therapy. On the contrary in latter 
lines of treatment, high levels of unselected LDH might be 
related to the heavy involvement of vital organs, such as 
the liver, regardless of the presence of an hypoxic drive.
Due to the independent prognostic role of all factors 
who have been included into the analysis, we hypothised 
that patients sub-groups with different clinical outcome 
during regorafenib treatment could be identified by taking 
into account all these factors combined. In particular, 
patients exhibiting a favourable profile (i.e. those without 
poor predictive indicators) seemed to benefit the most 
from the use of regorafenib.
The retrospective nature of this analysis and the lack 
of a proper control group (patients analysed for all the 
factors taken into account that received only BSC opposed 
to regorafenib treatment) prevents from drawing definitive 
conclusions on the prognostic or predictive value of the 
clinical factors analysed. It must be said that our analysis 
showed, in the group of patients who did not have any risk 
factor, not only an improved OS but also a significantly 
Figure 7: Kaplan-Meier curves for median overall survival (OS) in pre-treated metastatic colorectal cancer patients 
receiving regorafenib according to risk scoring: high PLT (+1), high neutrophil (+1), high neutrophil/lymphocyte (+1), 
low lymphocyte (+2)
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improved PFS. This latter observation may suggest a 
predictive more than a prognostic value of such factors.
Based on our findings, we can speculate that mCRC 
patients showing pre-treatment high neutrophil level, high 
platelet level, low lymphocytes level or high NLR may not 
be optimal candidates for regorafenib treatment. In these 
patients the risk of toxicity may not be in fact entirely 
balanced by the presumably poor clinical benefit deriving 
from treatment.
We believe that, after confirmation in further 
prospectively stratified and larger series, these clinical 
factors may play a relevant role in guiding treatment 
decision and prognostic stratification for patients 
receiving regorafenib. It would also be interesting to 
verify whether other factors (such as regorafenib starting 
dose or lack of anti-VEGF therapy in previous lines) 
might affect survival during regorafenib monotherapy. 
However this correlation was not possible in our 
paper as all patients included had already received 
bevacizumab and were started on regorafenib at the full 
dose of 160 mg/die).
Laboratory exams such as white blood cell count 
have a substantial advantage if compared with, although 
“fashionable”, biomolecular analyses: reproducibility and 
simplicity to obtain results without the need to perform 
more invasive tests. This could prove crucial in a setting 
where the identification of different risk-groups represents 
a key-challenge for the treatment of this disease, 
particularly now that different options are available and 
many more are hopefully to come.
MATERIALS AND METHODS
Patients selection
Histologically-proven mCRC patients who received 
regorafenib monotherapy after failure of previous 
chemotherapy regimens based on all standard drugs active 
in this setting (oxaliplatin, irinotecan, 5FU, bevacizumab 
and either cetuximab or panitumumab in case of RAS wild 
type tumour) were eligible for analysis.
Patients received regorafenib into the CORRECT 
and CONSIGN trials at our Institution (Ancona, Italy), 
at the Medical Oncology Department of the “Fondazione 
Poliambulanza” (Brescia, Italy), or at the Oncology 
Department of the “Azienda Ospedaliero-Universitaria 
Pisana” (Pisa, Italy). All patients had already received 
treatment with bevacizumab, oxaliplatin, irinotecan, 5FU/
capecitabine and, in K-ras/RAS wild type patients, anti-
EGFR monoclonal antibodies.
Treatment schedule was as follows: regorafenib 
160 mg/die (day 1 to 21 every 28 days). Tumour 
response was evaluated every 8 weeks by clinicians’ 
assessment and according to the Response Evaluation 
Criteria in Solid Tumors (RECIST 1.1). LDH serum 
levels, neutrophil, lymphocyte and platelets count were 
collected within one month before the start of treatment. 
All patients should have started treatment at the dose of 
160 mg/die, subsequent dose reductions were performed 
on the basis of tolerance to treatment as assessed by 
treating clinicians.
Laboratory exams specifics
All laboratory exams where determined according 
to IFCC (International Federation of Clinical Chemistry 
and Laboratory Medicine) method. The assay has been 
conducted in Institution Laboratories certified for Quality 
control according to the present rules in Europe.
For study purposes, LDH levels for each patient was 
calculated as the ratio between LDH serum levels at the 
beginning of the treatment with regorafenib and the upper-
normal-limit (UNL) for the laboratory where the test was 
performed.
Neutrophil level was determined as the ratio 
between neutrophil level at the treatment start and the 
upper-normal-limit (UNL) for the laboratory where the 
test was performed. Lymphocyte level was determined 
as the ratio between lymphocyte level at the treatment 
start and the lower-limit-normal (LLN) for the laboratory 
where the test was performed.
Platelets level was determined as the ratio between 
platelets level at the treatment start and the upper-
normal-limit (UNL) for the laboratory where the test was 
performed.
By performing the ratio between the point value of 
the single test by the LLN and UNL, we standardized the 
values of the determinations between the 3 laboratories 
where tests were performed.
Cut-off values for LDH, neutrophil, lymphocyte, 
NLR and platelet levels were determined by receiver 
operating characteristics (ROC) curve analysis in the 
whole patients population, assuming PFS (>2 months) as 
a classification variable.
Statistical analysis
Statistical analysis was performed with the MedCalc 
package (MedCalc® v9.4.2.0).
The association between categorical variables was 
assessed by chi-square test.
Survival distribution was estimated by the 
Kaplan-Meier method. Significant differences in 
probability of relapsing between the strata were evaluated 
by log-rank test. Cox multiple regression analysis was 
used to assess the role of variables resulted significant at 
univariate analysis (multivariate analysis).
Other tested variables included gender (male vs. 
female), age ( <65 yrs vs. ≥ 65 yrs), RAS mutational 
status (wild type vs. mutated), metastatic sites (< 2 vs. 
≥ 2), previous adjuvant chemotherapy, previous systemic 
anticancer therapy (≤ 2 vs. 3 vs. ≥ 4).
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A significant level of 0.05 was chosen to assess the 
statistical significance.
For statistical analysis, OS and PFS were defined 
respectively as the interval between the start of treatment 
to death or last follow-up visit and as the interval between 
the start of treatment to clinical progression or death or 
last follow up visit if not progressed.
Correction for multiple testing errors has been 
performed by the Holm-Sidak method.
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